Jasper is a biotechnology company focused on enabling safer conditioning agents that expand the application of curative hematopoietic stem cell transplants and gene therapies. The company's lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem cell transplant.
Jasper Therapeutics total Funding
Jasper Therapeutics latest funding size
Time since last funding
|2 years ago|
Jasper Therapeutics investors
|Roche Venture Fund, Abingworth, Alexandria Venture Investments, Quiming Venture Partners USA, Supervisor Capital|
Jasper Therapeutics has 74 Twitter Followers. The number of followers has increased 9.2% month over month and increased 33.2% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
Who are Jasper Therapeutics key executives?
Jasper Therapeutics's key executives are Jeet Mahal, Judith Shizuru and Kevin Heller.
Who are Jasper Therapeutics competitors?
Competitors of Jasper Therapeutics include IDEXX, Particular Sciences and Althea.
Receive alerts for 300+ data fields across thousands of companies